pharma · Hypoparathyroidism (HP) in Adults · Chronic hypoparathyroidism
Ascendis Pharma
Ascendis Pharma Bone Diseases A/S
Ascendis Pharma Bone is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypoparathyroidism (HP) in Adults, Chronic hypoparathyroidism. NovaPharmaNews links 2 clinical program(s), 0 drug
Palo Alto, USA HQ
2010 Founded
5 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2010
- Employees
- 5
- Programs
- 2
- Drugs
- 3
- Patents
- 12
ASND0035
Phase 3 · small molecule · Chronic hypoparathyroidism
ASND0035 for Chronic hypoparathyroidism is a Phase 3 program (small_molecule) at Ascendis Pharma Bone Diseases A/S with 1 ClinicalTrials.gov record(s).
Internal code ASND0035
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ascendis Pharma Bone Diseases A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chronic hypoparathyroidism
- Status
- active
- Trials
- 1